Skip to main content

Advertisement

Table 1 Comparison of characteristics between two groups of biliary tract cancer (BTC) patients undergoing microscopically margin-negative (R0) resection

From: The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection

Characteristic Adjuvant chemotherapy (n = 89) Observation (n = 64) P value
Age (years) a    0.072
Median (range) 64 (36–83) 67 (47–80)  
Gender    0.048
Male 50 (56.2) 46 (71.9)  
Female 39 (43.8) 18 (28.1)  
Tumor location    0.480
Gallbladder 43 (48.3) 34 (53.1)  
Intrahepatic bile duct 33 (37.1) 18 (28.1)  
Perihilar bile duct 3 (3.4) 5 (7.8)  
Distal bile duct 10 (11.2) 7 (10.9)  
Histologic differentiation    0.225
Well 34 (38.2) 25 (39.1)  
Moderate 31 (34.8) 30 (46.9)  
Poor 17 (19.1) 7 (10.9)  
Unspecifiedb 7 (7.9) 2 (3.1)  
AJCC stage    0.152
I 26 (29.2) 29 (45.3)  
II 35 (39.3) 20 (31.2)  
III 18 (20.2) 12 (18.8)  
IVAc 10 (11.2) 3 (4.7)  
Lymph node involvement    0.426
Yes 23 (25.8) 13 (20.3)  
No 66 (74.2) 51 (79.7)  
CA 19-9 (U/mL) (n = 126) a, d    0.328
Median (range) 25.3 (0.1–11,150.0) 17.6 (0.6–9700.0)  
  1. AJCC American Joint Committee on Cancer (7th edition), CA 19-9 carbohydrate antigen 19-9
  2. aExcept these, other values are presented as number of patients with percentage in parentheses
  3. bIncludes undifferentiated carcinoma (n = 3), signet ring cell carcinoma (n = 2), carcinosarcoma (n = 2), pleomorphic carcinoma (n = 1), and large cell neuroendocrine carcinoma (n = 1)
  4. cAll patients had intrahepatic bile duct cancers; 12 patients had TxN1M0 disease and 1 had T4N0M0 disease
  5. dBaseline CA 19-9 levels were available for 77 patients in the adjuvant chemotherapy group and 49 patients in the observation group